The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR/ARHP Annual Meeting 2012: Can Studying Anticitrullinated Protein Antibodies Put Us on Track to Stop RA?

ACR/ARHP Annual Meeting 2012: Can Studying Anticitrullinated Protein Antibodies Put Us on Track to Stop RA?

January 1, 2013 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

WASHINGTON, D.C.—Identifying anticitrullinated protein antibodies (ACPA) as a critical marker of rheumatoid arthritis (RA) was a huge step, but deeper knowledge of how they work is crucial before therapies involving them can be used in the clinic and finely tailored for maximum benefit, a molecular medicine expert in rheumatology said in a session titled, “Prospects for Prevention and Cure of Rheumatoid Arthritis,” here at the 2012 ACR/ARHP Annual Meeting, held November 9–14 in Washington, D.C. [Editor’s Note: This session was recorded and is available via ACR SessionSelect at www.rheumatology.org.]

You Might Also Like
  • ACR/ARHP Annual Meeting 2012: Genes Not the Only Factor in Susceptibility to Rheumatoid Arthritis
  • ACR/ARHP Annual Meeting 2012: Serum Antibodies Offer Useful Clinical Insights into Systemic Sclerosis
  • ACR/ARHP Annual Meeting Offers Basic Science Track
Explore This Issue
January 2013
Also By This Author
  • Effectiveness of Tofacitinib with Methotrexate, Adalimumab Therapy Evaluated in Patients with RA

The Role of ACPA

The picture of ACPA and how it operates is becoming clearer all the time, said Lars Klareskog, MD, PhD, professor in the rheumatology unit and director of the Center for Molecular Medicine at the Karolinska Institute in Stockholm, Sweden. Researchers at his center and elsewhere recently have shed more light on the complexity of ACPA and its different targets, like citrullinated fibrinogen and citrullinated vimentin.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Recent work involving nearly 2,000 RA cases subdivided the disease based on different ACPA specificities and gauged how those subcategories were related to the presence of the shared epitope, HLA-DRB1, a hallmark of severe RA. The odds ratio of having the shared epitope varied widely.1

For those with ACPA specificities for both citrullinated alpha-enolase and vimentin, the likelihood of having the shared epitope was “extremely high,” Dr. Klareskog said. “This means, probably, that there are somewhat different mechanisms involved in driving the B-cell immunity against these different epitopes,” he said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Klareskog also noted work that examined the extent to which B cells produce ACPA, which included a finding that in these patients, about 25% of all the CD19+ B cells produced antibodies against citrullinated antigens.2,3

Harnessing these kinds of new insights will require a smarter approach in surveillance and modification of the immune process, he added. Approaches might include using existing, more conventional therapies in very specific contexts and therapies directly aimed at T-cell “tolerization” and at interference with specific antibody functions, he noted.

“We are in a new situation, and then we can begin to use these things,” Dr. Klareskog said. “We are doing these things, of course, in parallel in people with diabetes, with multiple sclerosis, and I would argue that we are in a much better situation with rheumatoid arthritis.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Early Detection Is Key

V. Michael Holers, MD, professor in the integrated department of immunology at the University of Colorado (UC) in Denver, said that RA is, “in principle, a preventable disease.” By looking at the patterns of biomarkers including ACPA and cytokines linked with imminent onset of the disease, researchers might be able to draw closer to therapies preventing RA, he said.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Rheumatoid Arthritis Tagged With: ACPA, ACR/ARHP Annual Meeting, anticitrullinated protein antibodies, RA, Research, Rheumatoid arthritisIssue: January 2013

You Might Also Like:
  • ACR/ARHP Annual Meeting 2012: Genes Not the Only Factor in Susceptibility to Rheumatoid Arthritis
  • ACR/ARHP Annual Meeting 2012: Serum Antibodies Offer Useful Clinical Insights into Systemic Sclerosis
  • ACR/ARHP Annual Meeting Offers Basic Science Track
  • ACR/ARHP Annual Meeting 2012: Fatigue for People with Rheumatoid Arthritis Rooted in Physiological and Psychological Factors

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)